Date: November 03, 2026

Regulatory Disclosure Summary

FDA Communication Context

The Company has become aware of action initiated by the Food and Drug Administration (FDA), Maharashtra, concerning certain stock of Patanjali Cow Ghee held by one of its super distributor/Food Business Operators (FBO) in Maharashtra.

Communication Details

  • The communication/order was issued to and received by the concerned super distributor/FBO, not directly to the Company
  • The Company obtained a copy of the communication for examination after being informed by the FBO

Product Sampling Status

  • FDA officials collected samples of concerned batches of Patanjali Cow Ghee for laboratory testing
  • As of the disclosure date (November 03, 2026), neither the Company nor the concerned FBO has received any authenticated laboratory test report establishing that samples failed prescribed quality parameters
  • The Company clarifies that collection of samples for testing alone does not establish adulteration, substandard quality, or any violation of applicable food safety standards

Regulatory Directions

  • Directions have been issued regarding the identified stock, including restriction on its sale pending further action
  • The sampling and directions do not contain any confirmed laboratory findings establishing adulteration or failure of quality standards

Company's Response and Commitment

  • The Company reiterates commitment to maintaining highest standards of product quality, consumer safety, and regulatory compliance
  • The Company is taking cognizance of the matter and seeking relevant details and supporting documents from the concerned FBO and regulatory authorities
  • The Company is fully willing to cooperate with authorities and facilitate independent verification of concerned batches
  • If any authenticated laboratory report establishes deviation from prescribed quality standards, the Company will examine findings and take appropriate corrective action according to applicable laws and regulations

Current Position and Future Disclosures

  • The Company believes conclusions regarding product quality should be based on authenticated laboratory findings and established regulatory procedures
  • Without laboratory reports establishing quality parameter failure, it is premature to conclude the product is adulterated or substandard
  • The Company is closely monitoring the matter and will make further disclosures to Stock Exchanges as required under SEBI regulations upon receipt of material developments or further directions from regulatory authorities

Not Specified Sections

  • KMP / Board / Auditor Changes
  • Dividend Declaration or Non-Declaration
  • Board Meeting Outcomes
  • Financial Results
  • Auditor's Report
  • Disinvestment / Strategic Actions
  • Media Release / Investor Communication